venture creation process
our vision
what we offer
what we look for
history, projects & portfolio

History, projects & portfolio

At the end of 2000, Alfred Nijkerk and Bart van den Berg established the idea for VenGen after a sabbatical following a successful exit of a pharmaceutical contract manufacturer they had jointly founded in 1996. They drafted the VenGen business model and together with Jaap Blaak founded VenGen in the spring of 2001. Since then, VenGen has looked intensely at more than 100 projects. See our Portfolio for the companies now being further developed and their press-releases for their specific accomplishments.

Overview of some major achievements:

May :

UbiQ's Triple E platform was published in Nature Chemical Biology

May :

Selista appointed as new Japanese distributor for the AGE Reader mu

February : Diagnoptics receives Chinese market approval for AGE Reader SU
April : Ubiquigent announces collaboration with UbiQ
March :

Diagnoptics appoints Forel Medical as new Polish distributor

December :

Diagnoptics appoints ANL Produkter AB as new Swedish distributor

UbiQ introduces di-ubiquitin VME probes
September : to-BBB announces positive data from Phase 1 Clinical Study
June : to-BBB announces 10 mioEUR financing
May : UbiQ announces collaboration with Avacta
March :

Breakthrough publication: AGE Reader in atherosclerosis

December : to-BBB strenghtens organization for further growth
October : High-Tech Grunder Fonds and Bayern Kapital lead investment in Photonics Healthcare
August : to-BBB receives IND approval for Novel Brain Cancer Drug 2B3-101
August : UbiQ expands to new offices and laboratories on the Amsterdam Science Park
June : UbiQ and Neuroscience Campus Amsterdam join forces to develop treatments for Parkinson's disease and other neurodegenerative diseases
May : DiagnOptics receives CE mark approval for their latest product, the AGE Reader mu
April : to-BBB closes EUR 2.5 million financing round to broaden clinical brain tumor study
March Intravacc and ViciniVax sign license agreement to advance the development of a novel vaccine against cervical cancer
February : UbiQ launches UbiQ-PEP custom ubiquitinated peptide service
November : to-BBB receives Frost&Sullivan Technology Innovation Award
October : DiagnOptics; Successful introduction of the AGE Reader mu
July : UbiQ presents on Ubiquitin Conference in Philadelphia, USA
July : to-BBB presents data on 2B3-201 for neuroinflammation
February : DiagnOptics and PATH partner on clinical project in India
January : FlexGen expands to new location
June : to-BBB starts clinical trial in patients with brain metastases
February : to-BBB realizes 4 mEUR investment round
December : UbiQ and Boston Biochem Inc to collaborate on di-Ubiquitin chains
October : UbiQ was founded as a spin-off from the Netherlands Cancer Institute (NKI)
March : to-BBB and GSK to collaborate on brain delivery of a biologic product
February : Photonics Healthcare was granted 250 kEUR NGI grant
November : to-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
September : to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
July : Professor Bart de Strooper and to-BBB to collaborate on brain delivery of anti-Alzheimer’s antibodies
June : FlexGen among FEM tech 25 winners
March : FlexGen closes new round of financing by BioGeneration Ventures and Crédit Agricole Private Equity
February : to-BBB moves into commercialization mode with former Genzyme international executive Willem van Weperen as new CEO
November : to-BBB and Taiwanese ITRI sign exclusive license agreement
March : DiagnOptics' AGE reader presented at the Conference of the American College of Cardiology in Chicago
July  Aescap Venture invests EUR 4 mio in to-BBB
June :

to-BBB was rated amongst the top 25 most promising high tech companies in 2007 by FEM Business 

February : First sales of AGE-readers (DiagnOptics) to GlaxoSmithKline
January : Completion of second financing round of to-BBB
November td> : Completion of first financing round of DiagnOptics (co-lead by VenGen) 
October : to-BBB secures grant from US not for profit organization 
September : Completion of first financing round of Lactive
DiagnOptics introduces the AGE Reader at the EASD meeting to 40,000 diabetes specialists
June : to-BBB was rated amongst the top 25 most promising high tech companies in 2005 by FEM business
Completion of first financing round of FlexGen 
May : to-BBB coverage in "Het Financieele Dagblad; Medisch paard van Troje"
to-BBB signs agreement with Genmab 
April : Founding of Porifarma 
March : Founding of Lactive
to-BBB signs agreement with Biogen Idec
to-BBB first in tender IS grant  
February : Founding of FlexGen 
June : to-BBB was rated amongst the top 25 most promising high tech companies in 2004 by FEM business 
May : DiagnOptics receives a grant from the University and local government to accelerate promising start-ups 
February : Lactive signs a collaboration agreement with Animal Sciences Group of Wageningen University 
January : VenGen assists a spin-out company in Groningen in developing a business plan and financing proposition 
December : Lactive was granted the second phase of a BioPartner First Stage Grant 
August : Lactive secures first part of a BioPartner First Stage Grant 
June : to-BBB was awarded the New Venture fourth prize 
April : VenGen co-founds a drug development company that was liquidated in a later stage
December : Porifarma secures second phase of BioPartner First Stage Grant 
November : A VenGen project was granted a BioPartner First Stage Grant 
August : A VenGen project was granted a BioPartner First Stage Grant 
June : to-BBB secures second phase of STIGON grant
A VenGen project was awarded the New Venture first prize - initiated by McKinsey & Company - for the most innovative project
Completion of a financing round as intermediary for a life science company 
copyright 2021 - VenGen - disclaimer